|
|
Paul is co-head of the firm’s Securities and Public Companies practice. Paul represents public companies in business combinations and securities offerings, regularly advising clients on tender offers and mergers, on corporate governance issues, and on public and private sales of common stock, convertible notes, and debt instruments. He frequently handles matters involving biotechnology, medical device, and pharmaceutical companies — including Covidien, Cubist, Ironwood, Novavax, and Pfizer — and he has substantial experience representing entities organized in Massachusetts.
- Supernus Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS diseases, in its $50 million IPO.
- URL Pharma, a leading specialty pharmaceutical company, in its pending sale to Takeda for $800 million in cash plus contingent earn-out payments.
- Cubist Pharmaceuticals, a leading biopharmaceutical company, in a variety of corporate and securities matters, including its 2011 acquisition of Adolor Corporation for $215 million in cash plus contingent payment rights and, in 2010, a $450 million convertible note offering.
- Pfizer, the world's largest research-based pharmaceutical company, in a variety of corporate and securities matters, including its 2011 acquisition of Excaliard Pharmaceuticals, a biopharmaceutical company focused on the development of novel drugs for the treatment of skin scarring, and its 2011 acquisition of Icagen, a biopharmaceutical company focused on small molecule drugs that modulate ion channel targets.
- Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, in its 2010 $202 million IPO and its 2012 $85 million follow-on offering.
- Genzyme Corporation, one of the world’s leading biotechnology companies, in a variety of corporate matters, including its 2011 sale to Sanofi for $20.1 billion in cash plus contingent value rights and, in 2010, a proxy contest with entities affiliated with Carl Icahn, a cooperation agreement with Relational Investors, a $1 billion 144A debt offering, a $1 billion accelerated share repurchase program, the $925 million sale of its Genetics business unit to Laboratory Corporation of America Holdings, and the $265 million sale of its Diagnostics business unit to Sekisui Chemicals Co.
- Stryker, one of the world’s leading medical technology companies, in its 2011 acquisition of Concentric Medical, a medical device company focused on acute ischemic stroke intervention, for $135 million.
- inVentiv Health, a leading global provider of results-driven clinical, consulting and commercial services to the pharmaceutical and healthcare industries, in its 2011 acquisition of PharmaNet, a provider of global drug development services, on undisclosed financial terms, and in a related $390 million note offering.
- Underwriters, led by Citi, in the 2011 $54 million IPO of Tranzyme, a clinical-stage biopharmaceutical company.
- Covidien plc, a leading global provider of health care products, in several acquisitions, including, in 2010, its $2.7 billion acquisition of ev3, Inc., an endovascular device maker, and a related $1.5 billion debt offering.
Honors & Awards
- Chambers USA: America's Leading Lawyers for Business (2011)
- The Best Lawyers in America (2006-2012)
©1996-2012 Ropes & Gray LLP. All rights reserved.
|
|
Education
-
JD, with distinction, Stanford Law School, 1993
-
BA, summa cum laude, Boston College, 1988
Bar Admissions
- Massachusetts, 1995
- California, 1993
|
|